image
Lifecore Biomedical, Inc. LFCR
Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - US
Watchlist
$ 6.93
-0.997 %
$ 257 M
Market Cap
-4.73
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one LFCR stock under the worst case scenario is HIDDEN Compared to the current market price of 6.93 USD, Lifecore Biomedical, Inc. is HIDDEN

LFCR Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one LFCR stock under the base case scenario is HIDDEN Compared to the current market price of 6.93 USD, Lifecore Biomedical, Inc. is HIDDEN

LFCR Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one LFCR stock under the best case scenario is HIDDEN Compared to the current market price of 6.93 USD, Lifecore Biomedical, Inc. is HIDDEN

LFCR Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart LFCR

image
1M 8%
6M 8%
1Y 17%
3Y -31%
5Y -47%
All
$8.0$8.0$7.5$7.5$7.0$7.0$6.5$6.5$6.0$6.0$5.5$5.5$5.0$5.015 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '25
FINANCIALS
128 M REVENUE
24.20%
Growth Rates
1Year 24.20%
3Years -38.23%
5Years -25.46%
7Years -18.40%
10Years -12.31%
-8.84 M OPERATING INCOME
66.09%
Growth Rates
1Year 66.09%
3Years -8.82%
5Years -2.00%
7Years -6.66%
10Years -3.70%
9.33 M NET INCOME
109.13%
Growth Rates
1Year 109.13%
3Years 31.73%
5Years 86.73%
7Years -1.91%
10Years -7.03%
-217 K OPERATING CASH FLOW
99.37%
Growth Rates
1Year 99.37%
3Years -0.48%
5Years -0.27%
7Years -0.11%
10Years -0.10%
-17.9 M INVESTING CASH FLOW
-331.52%
Growth Rates
1Year -331.52%
3Years -18.19%
5Years 28.63%
7Years 4.65%
10Years -3.00%
7.51 M FINANCING CASH FLOW
-81.09%
Growth Rates
1Year -81.09%
3Years 61.29%
5Years -37.55%
7Years 16.16%
10Years 11.78%
35.2 M REVENUE
7.95%
Growth Rates
1Year 24.20%
3Years -38.23%
5Years -25.46%
7Years -18.40%
10Years -12.31%
-9.03 M OPERATING INCOME
-360.90%
Growth Rates
1Year 66.09%
3Years -8.82%
5Years -2.00%
7Years -6.66%
10Years -3.70%
-14.8 M NET INCOME
-124.76%
Growth Rates
1Year 109.13%
3Years 31.73%
5Years 86.73%
7Years -1.91%
10Years -7.03%
1.2 M OPERATING CASH FLOW
119.64%
Growth Rates
1Year 99.37%
3Years -0.48%
5Years -0.27%
7Years -0.11%
10Years -0.10%
1.54 M INVESTING CASH FLOW
162.51%
Growth Rates
1Year -331.52%
3Years -18.19%
5Years 28.63%
7Years 4.65%
10Years -3.00%
-6.78 M FINANCING CASH FLOW
-54.19%
Growth Rates
1Year -81.09%
3Years 61.29%
5Years -37.55%
7Years 16.16%
10Years 11.78%
Balance Sheet Lifecore Biomedical, Inc.
image
Current Assets 81 M
Cash & Short-Term Investments 8.46 M
Receivables 31.2 M
Other Current Assets 41.4 M
Non-Current Assets 173 M
Long-Term Investments 0
PP&E 151 M
Other Non-Current Assets 21.9 M
3.33 %12.27 %16.31 %59.47 %8.62 %Total Assets$254.0m
Current Liabilities 38.9 M
Accounts Payable 16.3 M
Short-Term Debt 4.91 M
Other Current Liabilities 17.6 M
Non-Current Liabilities 181 M
Long-Term Debt 125 M
Other Non-Current Liabilities 55.5 M
7.43 %8.02 %57.08 %25.24 %Total Liabilities$219.8m
EFFICIENCY
Earnings Waterfall Lifecore Biomedical, Inc.
image
Revenue 128 M
Cost Of Revenue 86.4 M
Gross Profit 41.8 M
Operating Expenses 49 M
Operating Income -8.84 M
Other Expenses -18.2 M
Net Income 9.33 M
140m140m120m120m100m100m80m80m60m60m40m40m20m20m00(20m)(20m)128m(86m)42m(49m)(9m)18m9mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
32.63% GROSS MARGIN
32.63%
Averages
1Year 32.63%
3Years 28.76%
5Years 22.79%
7Years 20.49%
10Years 18.43%
-6.90% OPERATING MARGIN
-6.90%
Averages
1Year -6.90%
3Years -10.10%
5Years -6.59%
7Years -4.59%
10Years -2.95%
9.37% NET MARGIN
9.37%
Averages
1Year 9.37%
3Years -38.13%
5Years -25.37%
7Years -17.39%
10Years -11.94%
22.29% ROE
22.29%
Averages
1Year 22.29%
3Years 1842.48%
5Years 1098.96%
7Years 786.49%
10Years 551.08%
4.39% ROA
4.39%
Averages
1Year 4.39%
3Years -17.09%
5Years -12.96%
7Years -8.32%
10Years -5.48%
-3.94% ROIC
-3.94%
Averages
1Year -3.94%
3Years -5.03%
5Years -3.54%
7Years -1.91%
10Years -1.00%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Lifecore Biomedical, Inc.
image
10m10m00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)(60m)(60m)201620162017201720182018201920192020202020212021202220222023202320242024
Net Income 9.33 M
Depreciation & Amortization 8.86 M
Capital Expenditures -17.9 M
Stock-Based Compensation 6.2 M
Change in Working Capital -3.84 M
Others -16.6 M
Free Cash Flow -18.1 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Lifecore Biomedical, Inc.
image
Wall Street analysts predict an average 1-year price target for LFCR of $6.5 , with forecasts ranging from a low of $5 to a high of $8 .
LFCR Lowest Price Target Wall Street Target
5 USD -27.85%
LFCR Average Price Target Wall Street Target
6.5 USD -6.20%
LFCR Highest Price Target Wall Street Target
8 USD 15.44%
Price
Max Price Target
Min Price Target
Average Price Target
88887777666655554444Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 7
6. Ownership
Insider Ownership Lifecore Biomedical, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
97.6 K USD 1
3-6 MONTHS
7.2 M USD 2
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lifecore Biomedical, Inc. (LFCR) and Encourages Shareholders to Learn More About the Investigation NEW YORK CITY, NY / ACCESS Newswire / May 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR. accessnewswire.com - 2 weeks ago
Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation NEW YORK CITY, NY / ACCESS Newswire / May 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR. accessnewswire.com - 2 weeks ago
Bronstein, Gewirtz & Grossman, LLC Encourages Lifecore Biomedical, Inc. (LFCR) Shareholders to Inquire about Securities Investigation NEW YORK CITY, NY / ACCESS Newswire / May 1, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR. accessnewswire.com - 2 weeks ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating Lifecore Biomedical, Inc. (LFCR) And Encourages Shareholders to Connect NEW YORK CITY, NY / ACCESS Newswire / April 29, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR. accessnewswire.com - 3 weeks ago
Laughing Water Capital Top 5 Investments (Q1 2025) Holding a meaningful cash position due to buyouts, providing optionality and safety amidst macro uncertainty, with plans to invest opportunistically. Lifecore Biomedical shows promise with strengthened balance sheet, improved sales force, and potential sale within 3 years, offering significant upside. NextNav's GPS technology investment faces short-term stock weakness but has positive FCC developments and strategic refinancing, indicating long-term potential. seekingalpha.com - 3 weeks ago
Bronstein, Gewirtz & Grossman, LLC Encourages Lifecore Biomedical, Inc. (LFCR) Stockholders to Inquire about Securities Investigation NEW YORK CITY, NY / ACCESS Newswire / April 24, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR. accessnewswire.com - 3 weeks ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lifecore Biomedical, Inc. (LFCR) and Encourages Investors to Learn More About the Investigation NEW YORK CITY, NY / ACCESS Newswire / April 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR. accessnewswire.com - 4 weeks ago
Lifecore Biomedical to Participate at Upcoming CDMO Live 2025 Conference CHASKA, Minn., April 22, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate in the upcoming CDMO Live 2025 conference. globenewswire.com - 4 weeks ago
Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation NEW YORK CITY, NY / ACCESS Newswire / April 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR. accessnewswire.com - 1 month ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating Lifecore Biomedical, Inc. (LFCR) And Encourages Investors to Connect NEW YORK CITY, NY / ACCESS Newswire / April 17, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR. accessnewswire.com - 1 month ago
Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CHASKA, Minn., April 16, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated contract development and manufacturing organization (“CDMO”), today announced that Lifecore granted a restricted stock unit (“RSU”) award with respect to 45,000 shares of its common stock, an option for 210,000 shares of stock, an RSU for 170,000 shares of common stock, and a performance stock unit (“PSU”) award for up to 370,000 shares of its common stock to Thomas D. Salus, Lifecore's newly hired chief legal and administration officer. The RSU awards, stock option and PSU award were granted April 14, 2025, pursuant to an employment agreement between Lifecore and Mr. Salus, and as a material inducement to Mr. Salus joining Lifecore as its chief legal and administration officer. globenewswire.com - 1 month ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lifecore Biomedical, Inc. (LFCR) and Encourages Stockholders to Learn More About the Investigation NEW YORK CITY, NY / ACCESS Newswire / April 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR. accessnewswire.com - 1 month ago
8. Profile Summary

Lifecore Biomedical, Inc. LFCR

image
COUNTRY US
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 257 M
Dividend Yield 0.00%
Description Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. It operates through Lifecore, Curation Foods, and Other segments. The Lifecore segment engages in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, including technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. This segment sells its non-HA products for medical use primarily in the ophthalmic, orthopedic, and other markets. The Curation Foods segment engages in processing, marketing, and selling of olive oils and wine vinegars under the O brand; and guacamole and avocado food products under the Yucatan and Cabo Fresh brands, as well as various private labels. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was incorporated in 1986 and is headquartered in Santa Maria, California.
Contact 3515 Lyman Boulevard, Chaska, MN, 55318 https://www.lifecore.com
IPO Date Feb. 15, 1996
Employees 524
Officers Mr. Aaron Perlitsh Director of Internal Audit & Chief Compliance Officer Ms. Jackie Q. Klecker Executive Vice President of Quality & Development Services Mr. Ryan D. Lake CPA EVice President & Chief Financial Officer Dr. Albert D. Bolles Ph.D. President of Curation Foods, Inc. Mr. Paul Josephs President, Chief Executive Officer & Director Mr. James G. Hall Advisor Mr. Thomas Salus Chief Legal and Administration Officer & Corporate Secretary Mr. Parker K. Javid Vice President Mr. Thomas Guldager Senior Vice President of Operations